Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
INFI Stock Overview
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.
Infinity Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.15 |
52 Week High | US$3.89 |
52 Week Low | US$0.46 |
Beta | 2 |
1 Month Change | 75.57% |
3 Month Change | 114.03% |
1 Year Change | -62.90% |
3 Year Change | -5.74% |
5 Year Change | 15.00% |
Change since IPO | -92.58% |
Recent News & Updates
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Shareholder Returns
INFI | US Biotechs | US Market | |
---|---|---|---|
7D | 43.8% | 1.2% | 3.2% |
1Y | -62.9% | -21.7% | -10.1% |
Return vs Industry: INFI underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: INFI underperformed the US Market which returned -11.7% over the past year.
Price Volatility
INFI volatility | |
---|---|
INFI Average Weekly Movement | 19.8% |
Biotechs Industry Average Movement | 12.5% |
Market Average Movement | 7.7% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INFI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: INFI's weekly volatility has increased from 14% to 20% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 23 | Adelene Perkins | https://www.infi.com |
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc. Fundamentals Summary
INFI fundamental statistics | |
---|---|
Market Cap | US$102.53m |
Earnings (TTM) | -US$46.79m |
Revenue (TTM) | US$2.22m |
46.3x
P/S Ratio-2.2x
P/E RatioIs INFI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INFI income statement (TTM) | |
---|---|
Revenue | US$2.22m |
Cost of Revenue | US$32.98m |
Gross Profit | -US$30.77m |
Other Expenses | US$16.02m |
Earnings | -US$46.79m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.52 |
Gross Margin | -1,387.78% |
Net Profit Margin | -2,110.33% |
Debt/Equity Ratio | 0% |
How did INFI perform over the long term?
See historical performance and comparison